{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:30:48Z","timestamp":1790188248278,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,10,25]],"date-time":"2016-10-25T00:00:00Z","timestamp":1477353600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,10,25]],"date-time":"2016-10-25T00:00:00Z","timestamp":1477353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Antiretroviral therapy containing an integrase strand transfer inhibitor (INSTI) plus two NRTIs has become the recommended treatment for antiretroviral-naive HIV-1-infected patients in the updated guidelines. We aimed to determine the prevalence of INSTI-related mutations in Taiwan. Genotypic resistance assays were performed on plasma from ARV-na\u00efve patients (N\u2009=\u2009948), ARV-experienced but INSTI-naive patients (N\u2009=\u2009359), and raltegravir-experienced patients (N\u2009=\u200963) from 2006 to 2015. Major INSTI mutations were defined according to the IAS-USA list and other substitutions with a Stanford HIVdb score \u2267\u200910 to at least one INSTI were defined as minor mutations. Of 1307 HIV-1 samples from patients never exposed to INSTIs, the overall prevalence of major resistance mutations to INSTIs was 0.9% (n\u2009=\u200912), with an increase to 1.2% in 2013. Of these 12 sequences, 11 harboured Q148H\/K\/R, one Y143R, and none N155H. Of 30 sequences (47.6%) with INSTI-resistant mutations from raltegravir-experienced patients, 17 harboured Q148H\/K\/R, 8 N155H, and 6 Y143C\/R. Other than these major mutations, the prevalence of minor mutations were 5.3% and 38.1%, respectively, in ARV-naive and raltegravir-experienced patients. The overall prevalence of INSTI mutations remains low in Taiwan. Surveillance of INSTI resistance is warranted due to circulation of polymorphisms contributing to INSTI resistance and expected increasing use of INSTIs.<\/jats:p>","DOI":"10.1038\/srep35779","type":"journal-article","created":{"date-parts":[[2016,10,25]],"date-time":"2016-10-25T10:27:10Z","timestamp":1477391230000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Prevalence of Integrase Strand Transfer Inhibitors (INSTI) Resistance Mutations in Taiwan"],"prefix":"10.1038","volume":"6","author":[{"given":"Sui-Yuan","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pi-Han","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Lin","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mao-Yuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-Yun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Szu-Min","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang-Huei","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Ching","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Hsin","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Fang","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Chun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Ching","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan-Chwen","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,10,25]]},"reference":[{"key":"BFsrep35779_CR1","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1016\/S0140-6736(12)60918-0","volume":"379","author":"E DeJesus","year":"2012","unstructured":"DeJesus, E. et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet 379, 2429\u20132438 (2012).","journal-title":"Lancet"},{"key":"BFsrep35779_CR2","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1310\/hct1304-228","volume":"13","author":"E DeJesus","year":"2012","unstructured":"DeJesus, E. et al. Efficacy of raltegravir versus efavirenz when combined with tenofovir\/emtricitabine in treatment-naive HIV-1-infected patients: week-192 overall and subgroup analyses from STARTMRK. HIV Clin Trials 13, 228\u2013232 (2012).","journal-title":"HIV Clin Trials"},{"key":"BFsrep35779_CR3","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S0140-6736(09)60918-1","volume":"374","author":"JL Lennox","year":"2009","unstructured":"Lennox, J. L. et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 374, 796\u2013806 (2009).","journal-title":"Lancet"},{"key":"BFsrep35779_CR4","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/S1473-3099(13)70257-3","volume":"13","author":"F Raffi","year":"2013","unstructured":"Raffi, F. et al. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis 13, 927\u2013935 (2013).","journal-title":"Lancet Infect Dis"},{"key":"BFsrep35779_CR5","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/QAI.0b013e31828ace69","volume":"63","author":"JK Rockstroh","year":"2013","unstructured":"Rockstroh, J. K. et al. Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir\/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK. J Acquir Immune Defic Syndr 63, 77\u201385 (2013).","journal-title":"J Acquir Immune Defic Syndr"},{"key":"BFsrep35779_CR6","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1016\/S0140-6736(12)60917-9","volume":"379","author":"PE Sax","year":"2012","unstructured":"Sax, P. E. et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet 379, 2439\u20132448 (2012).","journal-title":"Lancet"},{"key":"BFsrep35779_CR7","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","volume":"369","author":"SL Walmsley","year":"2013","unstructured":"Walmsley, S. L. et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med 369, 1807\u20131818 (2013).","journal-title":"N Engl J Med"},{"key":"BFsrep35779_CR8","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1097\/QAI.0b013e318289545c","volume":"63","author":"A Zolopa","year":"2013","unstructured":"Zolopa, A. et al. A randomized double-blind comparison of coformulated elvitegravir\/cobicistat\/emtricitabine\/tenofovir disoproxil fumarate versus efavirenz\/emtricitabine\/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results. J Acquir Immune Defic Syndr 63, 96\u2013100 (2013).","journal-title":"J Acquir Immune Defic Syndr"},{"key":"BFsrep35779_CR9","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1056\/NEJMoa0708978","volume":"359","author":"DA Cooper","year":"2008","unstructured":"Cooper, D. A. et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 359, 355\u2013365 (2008).","journal-title":"N Engl J Med"},{"key":"BFsrep35779_CR10","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.1093\/jac\/dkv202","volume":"70","author":"M Casadella","year":"2015","unstructured":"Casadella, M. et al. Primary resistance to integrase strand-transfer inhibitors in Europe. J Antimicrob Chemother 70, 2885\u20132888 (2015).","journal-title":"J Antimicrob Chemother"},{"key":"BFsrep35779_CR11","doi-asserted-by":"publisher","first-page":"3080","DOI":"10.1093\/jac\/dkv243","volume":"70","author":"T Doyle","year":"2015","unstructured":"Doyle, T. et al. Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades. J Antimicrob Chemother 70, 3080\u20133086 (2015).","journal-title":"J Antimicrob Chemother"},{"key":"BFsrep35779_CR12","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1093\/cid\/cit697","volume":"58","author":"CB Hurt","year":"2014","unstructured":"Hurt, C. B., Sebastian, J., Hicks, C. B. & Eron, J. J. Resistance to HIV integrase strand transfer inhibitors among clinical specimens in the United States, 2009\u20132012. Clin Infect Dis 58, 423\u2013431 (2014).","journal-title":"Clin Infect Dis"},{"key":"BFsrep35779_CR13","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1093\/jac\/dkq326","volume":"65","author":"F Ceccherini-Silberstein","year":"2010","unstructured":"Ceccherini-Silberstein, F. et al. Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors. J Antimicrob Chemother 65, 2305\u20132318 (2010).","journal-title":"J Antimicrob Chemother"},{"key":"BFsrep35779_CR14","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1093\/nar\/gkn1050","volume":"37","author":"O Delelis","year":"2009","unstructured":"Delelis, O. et al. The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation. Nucleic Acids Res 37, 1193\u20131201 (2009).","journal-title":"Nucleic Acids Res"},{"key":"BFsrep35779_CR15","doi-asserted-by":"publisher","first-page":"11440","DOI":"10.1128\/JVI.01168-09","volume":"83","author":"S Fransen","year":"2009","unstructured":"Fransen, S. et al. Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways. J Virol 83, 11440\u201311446 (2009).","journal-title":"J Virol"},{"key":"BFsrep35779_CR16","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1128\/AAC.01345-09","volume":"54","author":"EC Reuman","year":"2010","unstructured":"Reuman, E. C., Bachmann, M. H., Varghese, V., Fessel, W. J. & Shafer, R. W. Panel of prototypical raltegravir-resistant infectious molecular clones in a novel integrase-deleted cloning vector. Antimicrob Agents Chemother 54, 934\u2013936 (2010).","journal-title":"Antimicrob Agents Chemother"},{"key":"BFsrep35779_CR17","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1093\/jac\/dku535","volume":"70","author":"S Fourati","year":"2015","unstructured":"Fourati, S. et al. Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients. J Antimicrob Chemother 70, 1507\u20131512 (2015).","journal-title":"J Antimicrob Chemother"},{"key":"BFsrep35779_CR18","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1128\/AAC.01228-07","volume":"52","author":"I Malet","year":"2008","unstructured":"Malet, I. et al. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob Agents Chemother 52, 1351\u20131358 (2008).","journal-title":"Antimicrob Agents Chemother"},{"key":"BFsrep35779_CR19","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1093\/infdis\/jir636","volume":"204","author":"F Canducci","year":"2011","unstructured":"Canducci, F. et al. Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S\/GSK1349572) using clonal viral variants selected in patients failing raltegravir. J Infect Dis 204, 1811\u20131815 (2011).","journal-title":"J Infect Dis"},{"key":"BFsrep35779_CR20","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1128\/AAC.01209-10","volume":"55","author":"M Kobayashi","year":"2011","unstructured":"Kobayashi, M. et al. In Vitro antiretroviral properties of S\/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother 55, 813\u2013821 (2011).","journal-title":"Antimicrob Agents Chemother"},{"key":"BFsrep35779_CR21","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1093\/infdis\/jiu051","volume":"210","author":"A Castagna","year":"2014","unstructured":"Castagna, A. et al. Dolutegravir in antiretroviral-experienced patients with raltegravir- and\/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study. J Infect Dis 210, 354\u2013362 (2014).","journal-title":"J Infect Dis"},{"key":"BFsrep35779_CR22","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.1128\/JVI.06591-11","volume":"86","author":"PK Quashie","year":"2012","unstructured":"Quashie, P. K. et al. Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir. J Virol 86, 2696\u20132705 (2012).","journal-title":"J Virol"},{"key":"BFsrep35779_CR23","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1742-4690-10-22","volume":"10","author":"T Mesplede","year":"2013","unstructured":"Mesplede, T. et al. Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure. Retrovirology 10, 22 (2013).","journal-title":"Retrovirology"},{"key":"BFsrep35779_CR24","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1128\/AAC.01209-10","volume":"55","author":"M Kobayashi","year":"2011","unstructured":"Kobayashi, M. et al. In Vitro antiretroviral properties of S\/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother 55, 813\u2013821 (2011).","journal-title":"Antimicrob Agents Chemother"},{"key":"BFsrep35779_CR25","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1093\/cid\/ciu127","volume":"58","author":"CC Hung","year":"2014","unstructured":"Hung, C. C. et al. Increasing incidence of recent hepatitis D virus infection in HIV-infected patients in an area hyperendemic for hepatitis B virus infection. Clin Infect Dis 58, 1625\u20131633 (2014).","journal-title":"Clin Infect Dis"},{"key":"BFsrep35779_CR26","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1128\/JCM.06014-11","volume":"50","author":"HY Sun","year":"2012","unstructured":"Sun, H. Y. et al. Recent hepatitis C virus infections in HIV-infected patients in Taiwan: incidence and risk factors. J Clin Microbiol 50, 781\u2013787 (2012).","journal-title":"J Clin Microbiol"},{"key":"BFsrep35779_CR27","doi-asserted-by":"publisher","first-page":"e3222","DOI":"10.1371\/journal.pntd.0003222","volume":"8","author":"YC Lo","year":"2014","unstructured":"Lo, Y. C., Ji, D. D. & Hung, C. C. Prevalent and incident HIV diagnoses among Entamoeba histolytica-infected adult males: a changing epidemiology associated with sexual transmission\u2013Taiwan, 2006\u20132013. PLoS Negl Trop Dis 8, e3222 (2014).","journal-title":"PLoS Negl Trop Dis"},{"key":"BFsrep35779_CR28","doi-asserted-by":"publisher","first-page":"e008406","DOI":"10.1136\/bmjopen-2015-008406","volume":"5","author":"JC Tsai","year":"2015","unstructured":"Tsai, J. C. et al. Increasing incidence of recent hepatitis C virus infection among persons seeking voluntary counselling and testing for HIV and sexually transmitted infections in Taiwan. BMJ Open 5, e008406 (2015).","journal-title":"BMJ Open"},{"key":"BFsrep35779_CR29","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1111\/1469-0691.12529","volume":"20","author":"BR Wu","year":"2014","unstructured":"Wu, B. R. et al. Multicentre surveillance of prevalence of the 23S rRNA A2058G and A2059G point mutations and molecular subtypes of Treponema pallidum in Taiwan, 2009\u20132013. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases 20, 802\u2013807 (2014).","journal-title":"Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases"},{"key":"BFsrep35779_CR30","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1093\/jac\/dkn002","volume":"61","author":"SY Chang","year":"2008","unstructured":"Chang, S. Y. et al. Trends of antiretroviral drug resistance in treatment-naive patients with human immunodeficiency virus type 1 infection in Taiwan. J Antimicrob Chemother 61, 689\u2013693 (2008).","journal-title":"J Antimicrob Chemother"},{"key":"BFsrep35779_CR31","unstructured":"Lai, C. C. et al. Transmitted drug resistance of HIV-1 strains among individuals attending voluntary counselling and testing in Taiwan. J Antimicrob Chemother (2012)."},{"key":"BFsrep35779_CR32","unstructured":"Wensing, A. M. et al. Update of the Drug Resistance Mutations in HIV-1. Top Antivir Med 23, 132\u2013141 (2015)."},{"key":"BFsrep35779_CR33","doi-asserted-by":"publisher","first-page":"e4724","DOI":"10.1371\/journal.pone.0004724","volume":"4","author":"DE Bennett","year":"2009","unstructured":"Bennett, D. E. et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 4, e4724 (2009).","journal-title":"PLoS One"},{"key":"BFsrep35779_CR34","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1093\/jac\/dkv284","volume":"71","author":"CC Lai","year":"2016","unstructured":"Lai, C. C. et al. Transmitted drug resistance of HIV-1 strains among individuals attending voluntary counselling and testing in Taiwan. J Antimicrob Chemoth 71, 226\u2013234 (2016).","journal-title":"J Antimicrob Chemoth"},{"key":"BFsrep35779_CR35","doi-asserted-by":"publisher","first-page":"3087","DOI":"10.1093\/jac\/dkv205","volume":"70","author":"JR Santos","year":"2015","unstructured":"Santos, J. R. et al. Virological failure to raltegravir in Spain: incidence, prevalence and clinical consequences. J Antimicrob Chemother 70, 3087\u20133095 (2015).","journal-title":"J Antimicrob Chemother"},{"key":"BFsrep35779_CR36","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1093\/bioinformatics\/17.12.1244","volume":"17","author":"S Kumar","year":"2001","unstructured":"Kumar, S., Tamura, K., Jakobsen, I. B. & Nei, M. MEGA2: molecular evolutionary genetics analysis software. Bioinformatics 17, 1244\u20131245 (2001).","journal-title":"Bioinformatics"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep35779.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep35779","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep35779.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T01:56:08Z","timestamp":1672883768000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep35779"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,25]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,12,21]]}},"alternative-id":["BFsrep35779"],"URL":"https:\/\/doi.org\/10.1038\/srep35779","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,25]]},"assertion":[{"value":"19 February 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"35779"}}